20:45 , Sep 27, 2018 |  BC Innovations  |  Translation in Brief

Twice as splice

Abivax S.A. (Euronext:ABVX) has positioned its anti-HIV therapy ABX464 to take on inflammatory diseases after discovering the small molecule triggers RNA splicing that both halts HIV viral replication and boosts anti-inflammatory responses in HIV and...
16:42 , Sep 19, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method for differentiating HSPCs into megakaryocytes by overexpressing or activating one of 15 genes could help generate platelet-producing megakaryocyte colonies for thrombocytopenia. The method involves two steps: generating megakaryocyte progenitor cells...
16:42 , Sep 19, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds A heterocycloalkynylbenzimide-based dual DDR1/DDR2 inhibitor could be used to probe the role of two proteins in inflammatory diseases. Chemical synthesis and...
22:44 , Sep 13, 2018 |  BC Week In Review  |  Financial News

Kodiak files for IPO

Ophthalmic company Kodiak Sciences Inc. (Palo Alto, Calif.) filed to raise $100 million in an IPO on NASDAQ underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Chardan. Using its antibody biopolymer conjugate (ABC) platform,...
19:27 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts PGK1-knockout mice expressing an SP-C variant could be used to study the biology of idiopathic pulmonary fibrosis (IPF) and screen for therapies. Mice with inducible knockout of PGK1 that systemically expressed...
02:07 , Sep 10, 2018 |  BC Extra  |  Financial News

With anti-VEGF challenger in clinic, Kodiak files for IPO

Ophthalmic company Kodiak Sciences Inc. (Palo Alto, Calif.) filed to raise $100 million in an IPO on NASDAQ underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Chardan. Using its antibody biopolymer conjugate (ABC) platform,...
15:49 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation...
16:05 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Gastrointestinal Mouse studies suggest inhibiting JAK-1 and JAK-2, RAG2 or IL-6 could help treat Peutz-Jeghers syndrome, which involves the formation of benign gastrointestinal polyps. In a mouse model of the disease, systemic knockout of...
00:46 , Aug 4, 2018 |  BioCentury  |  Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...
16:04 , Jul 20, 2018 |  BC Week In Review  |  Company News

EUSA acquires global rights to J&J's Sylvant

Johnson & Johnson (NYSE:JNJ) granted EUSA Pharma Ltd. (Hemel Hempstead, U.K.) worldwide rights to Sylvant siltuximab for $115 million in cash. The chimeric mAb against IL-6 is approved in more than 40 countries, including the...